Generation of artificial proteoglycans containing glycosaminoglycan- modified CD44: Demonstration of the interaction between rates and chondroitin sulfate

Edith A. Wolff, Brad Greenfield, Dennis D. Taub, William J Murphy, Kelly L. Bennett, Alejandro Aruffo

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

All CD44 isoforms are modified with chondroitin sulfate (CS), while only those containing variably spliced exon V3 are modified with both CS and heparan sulfate (ITS). The CS is added to a serine-glycine (SG) site in CD44 exon E5, while HS and CS are added to the SGSG site in exon V3. Site-directed mutagenesis and other molecular biology techniques were used to determine the minimal motifs responsible for the addition of CS and HS to CD44 (see accompanying paper (Greenfield, B., Wang, W.-C., Marquardt, H., Piepkorn, M., Wolff, E.A., Aruffo, A., and Bennett, K.L. (1999) J. Biol. Chem. 274, 2511- 2517)). We have used this information to generate artificial proteoglycans containing the extracellular domain of the cell adhesion protein lymphocyte function-associated antigen-3 (LFA-3) (CD58) and CD44 motifs modified with CS or a combination of CS and HS. Analysis of the CD44-modified LFA-3 protein showed that it retains the ability to engage and trigger the function of its natural ligand CD2, resulting in T cell activation. In addition, the glycosaminoglycan-modified artificial proteoglycan is capable of binding the chemokine RANTES (regulated upon activation, normally T cell expressed and secreted) and delivering it to human T cells, resulting in enhanced T cell activation. These data demonstrate that artificial proteoglycans can be engineered with functional domains that have enhanced activity by codelivering glycosaminoglycan-binding molecules. The artificial proteoglycans were also used as a model system to explore the glycosaminoglycan binding properties of basic-fibroblast growth factor and the chemokine RANTES. While basic-fibroblast growth factor was shown to bind HS alone, this model revealed that RANTES binds not only HS, as has been demonstrated in the past, but also CS. Thus, artificial proteoglycans can be used for studying the glycosaminoglycan binding patterns of growth factors and chemokines and provide a means to manipulate the levels, types, and activity of glycosaminoglycan-binding proteins in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)2518-2524
Number of pages7
JournalJournal of Biological Chemistry
Volume274
Issue number4
DOIs
StatePublished - Jan 22 1999
Externally publishedYes

Fingerprint

Chondroitin Sulfates
Proteoglycans
Glycosaminoglycans
T-cells
Demonstrations
T-Lymphocytes
Chemical activation
CD58 Antigens
Chemokines
Exons
Fibroblast Growth Factor 2
Mutagenesis
Molecular biology
Heparitin Sulfate
Cell adhesion
Site-Directed Mutagenesis
Cell Adhesion
Glycine
Serine
Molecular Biology

ASJC Scopus subject areas

  • Biochemistry

Cite this

Generation of artificial proteoglycans containing glycosaminoglycan- modified CD44 : Demonstration of the interaction between rates and chondroitin sulfate. / Wolff, Edith A.; Greenfield, Brad; Taub, Dennis D.; Murphy, William J; Bennett, Kelly L.; Aruffo, Alejandro.

In: Journal of Biological Chemistry, Vol. 274, No. 4, 22.01.1999, p. 2518-2524.

Research output: Contribution to journalArticle

Wolff, Edith A. ; Greenfield, Brad ; Taub, Dennis D. ; Murphy, William J ; Bennett, Kelly L. ; Aruffo, Alejandro. / Generation of artificial proteoglycans containing glycosaminoglycan- modified CD44 : Demonstration of the interaction between rates and chondroitin sulfate. In: Journal of Biological Chemistry. 1999 ; Vol. 274, No. 4. pp. 2518-2524.
@article{2a4a0188c98a4cdfa7155fec791bf340,
title = "Generation of artificial proteoglycans containing glycosaminoglycan- modified CD44: Demonstration of the interaction between rates and chondroitin sulfate",
abstract = "All CD44 isoforms are modified with chondroitin sulfate (CS), while only those containing variably spliced exon V3 are modified with both CS and heparan sulfate (ITS). The CS is added to a serine-glycine (SG) site in CD44 exon E5, while HS and CS are added to the SGSG site in exon V3. Site-directed mutagenesis and other molecular biology techniques were used to determine the minimal motifs responsible for the addition of CS and HS to CD44 (see accompanying paper (Greenfield, B., Wang, W.-C., Marquardt, H., Piepkorn, M., Wolff, E.A., Aruffo, A., and Bennett, K.L. (1999) J. Biol. Chem. 274, 2511- 2517)). We have used this information to generate artificial proteoglycans containing the extracellular domain of the cell adhesion protein lymphocyte function-associated antigen-3 (LFA-3) (CD58) and CD44 motifs modified with CS or a combination of CS and HS. Analysis of the CD44-modified LFA-3 protein showed that it retains the ability to engage and trigger the function of its natural ligand CD2, resulting in T cell activation. In addition, the glycosaminoglycan-modified artificial proteoglycan is capable of binding the chemokine RANTES (regulated upon activation, normally T cell expressed and secreted) and delivering it to human T cells, resulting in enhanced T cell activation. These data demonstrate that artificial proteoglycans can be engineered with functional domains that have enhanced activity by codelivering glycosaminoglycan-binding molecules. The artificial proteoglycans were also used as a model system to explore the glycosaminoglycan binding properties of basic-fibroblast growth factor and the chemokine RANTES. While basic-fibroblast growth factor was shown to bind HS alone, this model revealed that RANTES binds not only HS, as has been demonstrated in the past, but also CS. Thus, artificial proteoglycans can be used for studying the glycosaminoglycan binding patterns of growth factors and chemokines and provide a means to manipulate the levels, types, and activity of glycosaminoglycan-binding proteins in vitro and in vivo.",
author = "Wolff, {Edith A.} and Brad Greenfield and Taub, {Dennis D.} and Murphy, {William J} and Bennett, {Kelly L.} and Alejandro Aruffo",
year = "1999",
month = "1",
day = "22",
doi = "10.1074/jbc.274.4.2518",
language = "English (US)",
volume = "274",
pages = "2518--2524",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "4",

}

TY - JOUR

T1 - Generation of artificial proteoglycans containing glycosaminoglycan- modified CD44

T2 - Demonstration of the interaction between rates and chondroitin sulfate

AU - Wolff, Edith A.

AU - Greenfield, Brad

AU - Taub, Dennis D.

AU - Murphy, William J

AU - Bennett, Kelly L.

AU - Aruffo, Alejandro

PY - 1999/1/22

Y1 - 1999/1/22

N2 - All CD44 isoforms are modified with chondroitin sulfate (CS), while only those containing variably spliced exon V3 are modified with both CS and heparan sulfate (ITS). The CS is added to a serine-glycine (SG) site in CD44 exon E5, while HS and CS are added to the SGSG site in exon V3. Site-directed mutagenesis and other molecular biology techniques were used to determine the minimal motifs responsible for the addition of CS and HS to CD44 (see accompanying paper (Greenfield, B., Wang, W.-C., Marquardt, H., Piepkorn, M., Wolff, E.A., Aruffo, A., and Bennett, K.L. (1999) J. Biol. Chem. 274, 2511- 2517)). We have used this information to generate artificial proteoglycans containing the extracellular domain of the cell adhesion protein lymphocyte function-associated antigen-3 (LFA-3) (CD58) and CD44 motifs modified with CS or a combination of CS and HS. Analysis of the CD44-modified LFA-3 protein showed that it retains the ability to engage and trigger the function of its natural ligand CD2, resulting in T cell activation. In addition, the glycosaminoglycan-modified artificial proteoglycan is capable of binding the chemokine RANTES (regulated upon activation, normally T cell expressed and secreted) and delivering it to human T cells, resulting in enhanced T cell activation. These data demonstrate that artificial proteoglycans can be engineered with functional domains that have enhanced activity by codelivering glycosaminoglycan-binding molecules. The artificial proteoglycans were also used as a model system to explore the glycosaminoglycan binding properties of basic-fibroblast growth factor and the chemokine RANTES. While basic-fibroblast growth factor was shown to bind HS alone, this model revealed that RANTES binds not only HS, as has been demonstrated in the past, but also CS. Thus, artificial proteoglycans can be used for studying the glycosaminoglycan binding patterns of growth factors and chemokines and provide a means to manipulate the levels, types, and activity of glycosaminoglycan-binding proteins in vitro and in vivo.

AB - All CD44 isoforms are modified with chondroitin sulfate (CS), while only those containing variably spliced exon V3 are modified with both CS and heparan sulfate (ITS). The CS is added to a serine-glycine (SG) site in CD44 exon E5, while HS and CS are added to the SGSG site in exon V3. Site-directed mutagenesis and other molecular biology techniques were used to determine the minimal motifs responsible for the addition of CS and HS to CD44 (see accompanying paper (Greenfield, B., Wang, W.-C., Marquardt, H., Piepkorn, M., Wolff, E.A., Aruffo, A., and Bennett, K.L. (1999) J. Biol. Chem. 274, 2511- 2517)). We have used this information to generate artificial proteoglycans containing the extracellular domain of the cell adhesion protein lymphocyte function-associated antigen-3 (LFA-3) (CD58) and CD44 motifs modified with CS or a combination of CS and HS. Analysis of the CD44-modified LFA-3 protein showed that it retains the ability to engage and trigger the function of its natural ligand CD2, resulting in T cell activation. In addition, the glycosaminoglycan-modified artificial proteoglycan is capable of binding the chemokine RANTES (regulated upon activation, normally T cell expressed and secreted) and delivering it to human T cells, resulting in enhanced T cell activation. These data demonstrate that artificial proteoglycans can be engineered with functional domains that have enhanced activity by codelivering glycosaminoglycan-binding molecules. The artificial proteoglycans were also used as a model system to explore the glycosaminoglycan binding properties of basic-fibroblast growth factor and the chemokine RANTES. While basic-fibroblast growth factor was shown to bind HS alone, this model revealed that RANTES binds not only HS, as has been demonstrated in the past, but also CS. Thus, artificial proteoglycans can be used for studying the glycosaminoglycan binding patterns of growth factors and chemokines and provide a means to manipulate the levels, types, and activity of glycosaminoglycan-binding proteins in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0033593212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033593212&partnerID=8YFLogxK

U2 - 10.1074/jbc.274.4.2518

DO - 10.1074/jbc.274.4.2518

M3 - Article

C2 - 9891023

AN - SCOPUS:0033593212

VL - 274

SP - 2518

EP - 2524

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 4

ER -